Navigation Links
GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference
Date:8/7/2013

LONDON, Aug. 8, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the 33rd Annual Canaccord Genuity Growth Conference on Wednesday, 14 August, 2013 at 2:00 p.m. ET. The conference will be held at the InterContinential Boston in Boston, MA.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section at www.gwpharm.com.

About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
2. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
3. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
4. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. HealthEconomics.Com Launches a New Specialty Pharma Newsletter to Worldwide Community of Industry Insiders Within Specialty Pharmaceuticals
7. Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
8. Piedmont Pharmaceuticals Gains FDA Approval of Animal Health Soft Chew Pain Medication
9. North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017
10. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
11. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
(Date:2/21/2017)... , Feb. 21, 2017 Synthetic Biologics, Inc. ... to preserve the microbiome to protect and restore the health of ... year ended December 31, 2016 on Thursday, March 2, 2017, and ... EST. The dial-in information for the call is as follows: ... ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS ... digital health applications, announced a partnership with Redox, a leader in cloud-based healthcare ... many clinical systems while keeping data secure in the cloud. , The digital ...
(Date:2/21/2017)... ... February 21, 2017 , ... Genedata, a leading provider of ... the establishment of Genedata Limited as a new subsidiary in the United Kingdom. ... life science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to collaborate closely ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
Breaking Biology News(10 mins):